"Fair enough. And just my last question, could you maybe break out the acquisition contribution of what you expect Quantim and JATA to contribute in 2013 and maybe how we should think about the linearity of those -- of the revenue flow for those acquisitions as well?
Paul A. Ricci - Chairman and Chief Executive Officer
Well, we don't historically provide specific revenue guidance around acquisitions, but we realize these are 2 meaningful acquisitions, and a reasonable estimate for you might be $90 million to $100 million for the full year with some skewering towards the second half of the year. It's difficult though to be more specific in part because those revenues will be blended with other revenues from our Healthcare business in provider-wide contracts that we expect to do that comprehend various revenue and product and services streams."
So, can we assume Ricci paid approx. $550m for about $100 m in annual revenue?